<rt id="6oue2"><center id="6oue2"></center></rt>
Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Partnerships expand access to quality treatment, cut cost of medical services

By ZHOU WENTING in Shanghai | China Daily | Updated: 2021-12-10 09:58
Share
Share - WeChat
A training director with German medical tech company Siemens Healthineers introduces a surgery robot to medical staff at Boao Super Hospital in Hainan province on March 13. [Photo/China Daily]

Improving drug accessibility and affordability is considered a very important part of the innovative health ecosystem the country is building. To help make that goal a reality, multinational pharmaceutical companies have said that they are willing to work with local partners.

China has formed what is, in effect, a multilevel medical security system with basic medical insurance as the main support, backed by supplementary medical insurance, commercial health insurance and charitable donations, experts said.

By August, commercial, supplementary medical insurance had become available in 75 cities. The reimbursement lists of such insurance plans included some innovative drugs made by multinational pharmaceutical giants for the treatment of major diseases such as breast cancer and lung cancer.

"That allowed patients to benefit from high-quality medical services while lessening the financial burden," said Chen Hao, an expert at Tongji Medical College of Huazhong University of Science and Technology. Chen spoke at an event held by Pfizer during the fourth China International Import Expo in November.

Policies such as one that created the Hainan Boao Lecheng International Medical Tourism Pilot Zone also have been shown to play a role in accelerating the introduction of innovative drugs in the domestic market.

Ye Gang, an oncology expert at Boao Evergrande International Hospital, said that more than 10 lung cancer patients had received an innovative targeted therapy designed by Pfizer since the therapy's introduction last year.

Novartis and the Lecheng pilot zone administration also signed a strategic cooperation memorandum at CIIE, aiming to leverage real-world data to verify the efficacy and safety of drugs, and thereby help drug regulatory authorities make decisions and accelerate the approval of innovative medicines.

"By combining real-world evidence with evidence from clinical trials completed overseas, we'll create a new pathway for global innovative drugs and devices to be launched in China in an accelerated way," said Lyu Xiaolei, deputy director of the zone's administration.

Multinational pharmaceutical companies have contributed in other ways to the country's health ecosystem construction, such as forming partnerships with startup companies and empowering chronic disease management.

Novartis and Shanghai Zhangjiang Group signed a memorandum of understanding during the CIIE to set up the Novartis China Life Sciences Open Innovation Platform.

The platform will leverage the company's global innovation resources to help incubate and accelerate local innovative projects in biopharmaceutical and life sciences.

GlaxoSmithKline announced it would promote a "happy breathing" initiative, which it had begun with the China Association of Health Promotion and Education in 2017 to standardize diagnosis and treatment of chronic obstructive pulmonary disease, or COPD. The announcement marks a fourth phase of the initiative, covering wider regions and establishing a system augmented by artificial intelligence to assist doctors' decision-making.

"By August, the initiative had covered 29 cities in 24 provincial-level regions, holding nearly 600 doctor training sessions, surveying 1.51 million patients, and including 36,900 COPD patients in the standardized management system," said Huang Zemin, executive vice-president of the association.

Boehringer Ingelheim and Chengdu's Wenjiang district government last month announced a plan to build a German gold-standard stroke rehabilitation center at Chengdu Medical City, a biomedical innovation center. The stroke center is expected to help improve stroke rehabilitation in the province and in western China.

Chengdu is the second Chinese city in which Consanas Rehabilitation, a stroke rehabilitation brand of Boehringer Ingelheim, will operate a center following its first in Shanghai in 2018.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
做你的猫PR社,网红国产福利电影,美乳高清无码下载,国产原创麻豆剧三区,www啪啪岛国黄色,插痛卡一卡二卡三在线播放,国产闪现福利,91视频高三毕业金橘色,短视频国产91 avav亚洲电影| 亚洲 欧洲 偷拍 台湾| 亚洲夜夜性无码国产盗摄www.qbwfo.com| 孕92日本国产视频| 国产剧情国产主播福利护士在线| 街边搭讪2小青蛙在线| 无码交流论坛| 绿岛电影院亚洲AV| 91影院天美麻豆| 足交视频污| 野外露出pr社| 家教女老师国产情景剧 两段磁力| 国产人妖视频一区二区| 久久动漫尤物视频| 亚洲AV综合一区二区台湾| 免费观看黃色A一级视频_3| 麻豆女海王卢珊珊| 短视频国产91| 富姐调教奴隶视频| 国产浮力久久娱乐| 网红福利极品主播在线观看| 日本一区二区爱爱| 91网友自拍偷拍照片| 久久丝袜制服视频| 国产麻豆仓库| 在线韩国主播免费观看视频直播| 国产 视频| 免费公开视频97若怒| 快瞄午夜剧场| 国产女主SM视频论坛| 免费国产片偷情少妇| 堕美人妻在线播放| 亚洲国产日韩制服丝袜综合| 亚洲另类网红无码国产| 老司机午夜福利影院在线看22nt| 日本国产在线主播| 王者荣耀去衣||裸||成人||18百度网盘| pr萌汁社凌乱4分钟| 异族中出视频| 69影院啪啪看贝| 国产原创中文一区果冻| http://www.parafarmaciaesserebenessere.com http://www.snappydb.com http://www.neshaminycreeksideinn.com http://www.dariovitulli.com http://www.chambres-dordogne.com http://www.boutte-design.com